• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Uric acid and xantine-oxidase inhibitors in patients with gout: A re-assessment and an update.

作者信息

Borghi Claudio, Narkiewicz Krzysztof, Mancia Giuseppe

机构信息

Department of Medical and Surgical Sciences, University of Bologna, Italy.

Department of Hypertension and Diabetology, Medical University of Gdansk, Poland.

出版信息

Cardiol J. 2019;26(1):99-101. doi: 10.5603/CJ.2019.0015.

DOI:10.5603/CJ.2019.0015
PMID:30882192
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8086684/
Abstract
摘要

相似文献

1
Uric acid and xantine-oxidase inhibitors in patients with gout: A re-assessment and an update.痛风患者的尿酸与黄嘌呤氧化酶抑制剂：重新评估与更新
Cardiol J. 2019;26(1):99-101. doi: 10.5603/CJ.2019.0015.
2
The net clinical benefits of febuxostat versus allopurinol in patients with gout or asymptomatic hyperuricemia - A systematic review and meta-analysis.非布司他对比别嘌醇用于痛风或无症状高尿酸血症患者的净临床获益：一项系统评价和荟萃分析。
Nutr Metab Cardiovasc Dis. 2019 Oct;29(10):1011-1022. doi: 10.1016/j.numecd.2019.06.016. Epub 2019 Jun 24.
3
As compared to allopurinol, urate-lowering therapy with febuxostat has superior effects on oxidative stress and pulse wave velocity in patients with severe chronic tophaceous gout.与别嘌醇相比，非布司他降尿酸治疗对严重慢性痛风石性痛风患者的氧化应激和脉搏波速度具有更好的效果。
Rheumatol Int. 2014 Jan;34(1):101-9. doi: 10.1007/s00296-013-2857-2. Epub 2013 Sep 12.
4
An allopurinol-controlled, multicenter, randomized, double-blind, parallel between-group, comparative study of febuxostat in Chinese patients with gout and hyperuricemia.非布司他在中国痛风和高尿酸血症患者中的一项别嘌醇对照、多中心、随机、双盲、组间平行比较研究。
Int J Rheum Dis. 2014 Jul;17(6):679-86. doi: 10.1111/1756-185X.12266. Epub 2014 Jan 28.
5
Increase in thyroid stimulating hormone levels in patients with gout treated with inhibitors of xanthine oxidoreductase.接受黄嘌呤氧化还原酶抑制剂治疗的痛风患者促甲状腺激素水平升高。
Rheumatol Int. 2015 Nov;35(11):1857-61. doi: 10.1007/s00296-015-3355-5. Epub 2015 Sep 5.
6
Potency on lowering serum uric acid in gout patients: a pooled analysis of registrative studies comparing febuxostat vs. allopurinol.在降低痛风患者血尿酸方面的疗效：比较非布司他与别嘌醇的注册研究的汇总分析。
Eur Rev Med Pharmacol Sci. 2017 Sep;21(18):4186-4195.
7
Febuxostat: a selective xanthine-oxidase/xanthine-dehydrogenase inhibitor for the management of hyperuricemia in adults with gout.非布司他：一种选择性黄嘌呤氧化酶/黄嘌呤脱氢酶抑制剂，用于治疗成人痛风患者的高尿酸血症。
Clin Ther. 2009 Nov;31(11):2503-18. doi: 10.1016/j.clinthera.2009.11.033.
8
Febuxostat compared with allopurinol in patients with hyperuricemia and gout.非布司他与别嘌醇治疗高尿酸血症和痛风患者的比较。
N Engl J Med. 2005 Dec 8;353(23):2450-61. doi: 10.1056/NEJMoa050373.
9
Febuxostat--treatment for hyperuricemia and gout?非布司他——用于治疗高尿酸血症和痛风？
N Engl J Med. 2005 Dec 8;353(23):2505-7. doi: 10.1056/NEJMe058247.
10
Update on emerging urate-lowering therapies.新型降尿酸疗法的最新进展。
Curr Opin Rheumatol. 2009 Mar;21(2):143-9. doi: 10.1097/BOR.0b013e328325bd94.

本文引用的文献

1
Expert consensus for the diagnosis and treatment of patient with hyperuricemia and high cardiovascular risk.高尿酸血症合并高心血管疾病风险患者诊断和治疗的专家共识
Cardiol J. 2018;25(5):545-563. doi: 10.5603/CJ.2018.0116.
2
Gout, Xanthine Oxidase Inhibition, and Cardiovascular Outcomes.
Circulation. 2018 Sep 11;138(11):1127-1129. doi: 10.1161/CIRCULATIONAHA.118.036148.
3
Febuxostat Therapy for Patients With Stage 3 CKD and Asymptomatic Hyperuricemia: A Randomized Trial.非布司他治疗 3 期 CKD 合并无症状高尿酸血症患者：一项随机试验。
Am J Kidney Dis. 2018 Dec;72(6):798-810. doi: 10.1053/j.ajkd.2018.06.028. Epub 2018 Sep 1.
4
Assessment of Cardiovascular Risk in Older Patients With Gout Initiating Febuxostat Versus Allopurinol: Population-Based Cohort Study.评估起始用非布司他与别嘌醇治疗老年痛风患者的心血管风险：基于人群的队列研究。
Circulation. 2018 Sep 11;138(11):1116-1126. doi: 10.1161/CIRCULATIONAHA.118.033992.
5
Cardiovascular Safety of Febuxostat or Allopurinol in Patients with Gout.别嘌醇或非布司他治疗痛风患者的心血管安全性。
N Engl J Med. 2018 Mar 29;378(13):1200-1210. doi: 10.1056/NEJMoa1710895. Epub 2018 Mar 12.
6
Hyperuricemia, Acute and Chronic Kidney Disease, Hypertension, and Cardiovascular Disease: Report of a Scientific Workshop Organized by the National Kidney Foundation.高尿酸血症、急性和慢性肾脏病、高血压和心血管疾病：美国国家肾脏基金会组织的科学研讨会报告。
Am J Kidney Dis. 2018 Jun;71(6):851-865. doi: 10.1053/j.ajkd.2017.12.009. Epub 2018 Feb 27.
7
Cardiac and renal protective effects of urate-lowering therapy.降低尿酸治疗的心脏和肾脏保护作用。
Rheumatology (Oxford). 2018 Jan 1;57(suppl_1):i47-i50. doi: 10.1093/rheumatology/kex432.
8
2016 updated EULAR evidence-based recommendations for the management of gout.2016 年更新的 EULAR 痛风管理循证建议。
Ann Rheum Dis. 2017 Jan;76(1):29-42. doi: 10.1136/annrheumdis-2016-209707. Epub 2016 Jul 25.
9
Urate lowering therapies in the treatment of gout: a systematic review and meta-analysis.降低尿酸疗法在痛风治疗中的应用：一项系统评价与荟萃分析。
Eur Rev Med Pharmacol Sci. 2016 Mar;20(5):983-92.
10
Rationale, design, and baseline characteristics of a study to evaluate the effect of febuxostat in preventing cerebral, cardiovascular, and renal events in patients with hyperuricemia.一项评估非布司他对高尿酸血症患者预防脑、心血管和肾脏事件效果的研究的原理、设计及基线特征
J Cardiol. 2017 Jan;69(1):169-175. doi: 10.1016/j.jjcc.2016.02.015. Epub 2016 Apr 20.